NCT05755776招募中不适用
To Evaluate the Efficacy and Safety of Tenofovir Amibufenamide in Chronic Hepatitis B (CHB) Patients With Low-level Viraemia (LLV) After Entecavir Treatment
The Second Affiliated Hospital of Chongqing Medical University13 个研究点 分布在 1 个国家目标入组 204 人开始时间: 2023年3月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 204
- 试验地点
- 13
- 主要终点
- The proportions of undetectable HBV DNA in patients treated with ETV and TMF at week 48.
研究概览
简要总结
The goal of this observational study is to explore the efficacy and safety of Tenofovir Amibufenamide (TMF) in Entecavir (ETV) treated chronic hepatitis B patients with low-level viraemia. The main question it aims to answer is:
- The efficacy and safety of TMF in chronic hepatitis B patients with low-level viraemia.
- What is the appropriate treatment for ETV treated chronic hepatitis B patients with low-level viraemia.
Participants will choose to maintain their original regimen (ETV) or switch to TMF After being fully informed of the benefits and risks of treatment.
Researchers will compare ETV and TMF to see if there is a difference in the efficacy of the two drugs in chronic hepatitis B patients with low-level viraemia.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Must be able to understand and sign a written informed consent, which must be obtained prior to screening.
- •Male and non-pregnant, non-lactating female subjects who have reached the age of 18-65 years (based on the date of signed informed consent). Female subjects of childbearing age with a negative serum pregnancy test.
- •Documented signs of chronic HBV infection (e.g., HBsAg positive for more than 6 months.
- •Subjects treated with ETV over 1 year will be able to be enrolled in the study.
- •Subjects with 20 ≤ HBV-DNA < 2000 IU/mL at screening (including intermittent and continuous low-level viraeima).
- •Must be willing and able to comply with all study requirements.
排除标准
- •Female patients who are pregnant or breastfeeding or who plan to become pregnant during the study period.
- •Men and women of childbearing potential who are unwilling to use an "effective" method of contraception as defined in the protocol during the study period.
- •Co-infection with HAV HCV, HIV, HDV or HEV; or co-infection with autologous liver, metabolism-related fatty liver, or drug-induced liver injury.
- •Diagnosis of hepatocellular carcinoma by imaging (with evidence of hepatocellular carcinoma)
- •Patients who have received a solid organ or bone marrow transplant
- •History of malignancy within 5 years prior to screening, except for specific tumors cured by surgical resection (basal cell dermal skin cancer, etc.); patients evaluated for probable malignancy were ineligible.
- •Currently receiving treatment with immunomodulators (e.g., corticosteroids), investigational drugs, nephrotoxic drugs, or drugs capable of regulating renal excretion. Drugs that modulate renal excretion.
- •Renal, cardiovascular, pulmonary, or neurological disease that is considered severe by the investigator.
- •Severe bone disease (e.g., osteochondrosis, chronic osteomyelitis, osteogenesis imperfecta, chondromalacia) or multiple fractures.
- •Subjects receiving a contraindicated combination drug (subjects receiving a contraindicated drug require a minimum 30-day washout period) and known hypersensitivity reactions to study drugs, metabolites or formulation excipients.
- •Current alcohol or drug abuse that, in the investigator's judgment, may interfere with the subject's compliance with study requirements.
- •Any other clinical condition that, in the opinion of the investigator, would render the subject unsuitable for the study or unable to comply with the dosing requirements medical condition or prior treatment.
- •Prior or existing clinical liver failure (Child-Pugh score ≥ grade B).
研究组 & 干预措施
TMF group
Participants in this group will switch to TMF 25 mg, daily until the end of the study.
干预措施: TMF (Drug)
结局指标
主要结局
The proportions of undetectable HBV DNA in patients treated with ETV and TMF at week 48.
时间窗: 48 weeks
Undetectable HBV DNA is defined as below 20 IU/mL.
次要结局
- The proportions of undetectable pgRNA in patients treated with ETV and TMF at week 24 and 48.(24 weeks and 48 weeks)
- The proportions of undetectable HBV DNA in patients treated with ETV and TMF at week 24.(24 weeks)
- The proportions of ALT normalization in patients treated with ETV and TMF at week 24 and 48.(24 weeks and 48 weeks)
- Comparing pgRNA levels from baseline at week 24 and 48.(24 weeks and 48 weeks)
- Comparing HBcrAg levels from baseline at week 24 and 48.(24 weeks and 48 weeks)
- Comparing degree of liver fibrosis from baseline at week 24 and 48.(24 weeks and 48 weeks)
- The proportions of undetectable HBcrAg in patients treated with ETV and TMF at week 24 and 48.(24 weeks and 48 weeks)
- Comparing the change of creatinine clearance rate from baseline at week 24 and 48.(24 weeks and 48 weeks)
- The types, incidence and severity of adverse events and serious adverse events during treatment were evaluated in both groups(Week 48)
研究者
研究点 (13)
Loading locations...
相似试验
Unknown
4 期
Preventing Mother-to-child Transmission of Hepatitis B Virus With Tenofovir Alafenamide (TAF)Hepatitis B, ChronicMother to Child TransmissionNCT05177926Nanfang Hospital, Southern Medical University330
已完成
3 期
Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Negative for Hepatitis B e AntigenHBeAg-negative Chronic Hepatitis BNCT01940341Gilead Sciences426
已完成
3 期
Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Negative Hepatitis B (China)HBVChronic HBV InfectionNCT02836236Gilead Sciences155
已完成
3 期
Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Positive Hepatitis B (China)HBVChronic HBV InfectionNCT02836249Gilead Sciences181
已完成
3 期
Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Positive for Hepatitis B e AntigenHBeAg-positive Chronic Hepatitis BNCT01940471Gilead Sciences875